Opportunities for Improving Cancer Treatment Using Systems Biology

Overview

Journal Curr Opin Syst Biol

Date 2020 Jun 11

PMID 32518857

Citations 3

Authors

Jason I Griffiths

Adam L Cohen

Veronica Jones

Ravi Salgia

Jeffrey T Chang

Andrea H Bild

Affiliations

Soon will be listed here.

Abstract

Current cancer therapies target a limited set of tumor features, rather than considering the tumor as a whole. Systems biology aims to reveal therapeutic targets associated with a variety of facets in an individual's tumor, such as genetic heterogeneity and its evolution, cancer cell-autonomous phenotypes, and microenvironmental signaling. These disparate characteristics can be reconciled using mathematical modeling that incorporates concepts from ecology and evolution. This provides an opportunity to predict tumor growth and response to therapy, to tailor patient-specific approaches in real time or even prospectively. Importantly, as data regarding patient tumors is often available from only limited time points during treatment, systems-based approaches can address this limitation by interpolating longitudinal events within a principled framework. This review outlines areas in medicine that could benefit from systems biology approaches to deconvolve the complexity of cancer.

Citing Articles

Treatment of evolving cancers will require dynamic decision support.

Strobl M, Gallaher J, Robertson-Tessi M, West J, Anderson A Ann Oncol. 2023; 34(10):867-884.

PMID: 37777307 PMC: 10688269. DOI: 10.1016/j.annonc.2023.08.008.

Path to Clonal Theranostics in Luminal Breast Cancers.

Hajjaji N, Aboulouard S, Cardon T, Bertin D, Robin Y, Fournier I Front Oncol. 2022; 11:802177.

PMID: 35096604 PMC: 8793283. DOI: 10.3389/fonc.2021.802177.

Group Behavior and Emergence of Cancer Drug Resistance.

Bhattacharya S, Mohanty A, Achuthan S, Kotnala S, Jolly M, Kulkarni P Trends Cancer. 2021; 7(4):323-334.

PMID: 33622644 PMC: 8500356. DOI: 10.1016/j.trecan.2021.01.009.

References

Anchang B, Davis K, Fienberg H, Williamson B, Bendall S, Karacosta L . DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity. Proc Natl Acad Sci U S A. 2018; 115(18):E4294-E4303. PMC: 5939057. DOI: 10.1073/pnas.1711365115. View

Labelle M, Hynes R . The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012; 2(12):1091-9. PMC: 3540992. DOI: 10.1158/2159-8290.CD-12-0329. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

Chen P, Zhao D, Li J, Liang X, Li J, Chang A . Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma. Cancer Cell. 2019; 35(6):868-884.e6. PMC: 6561349. DOI: 10.1016/j.ccell.2019.05.003. View

Iknayan K, Tingley M, Furnas B, Beissinger S . Detecting diversity: emerging methods to estimate species diversity. Trends Ecol Evol. 2013; 29(2):97-106. DOI: 10.1016/j.tree.2013.10.012. View

Rajappa S, Krishna M, Narayanan P . Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment. Adv Ther. 2019; 36(6):1279-1290. DOI: 10.1007/s12325-019-00917-6. View

Maj E, Papiernik D, Wietrzyk J . Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Int J Oncol. 2016; 49(5):1773-1784. PMC: 5063425. DOI: 10.3892/ijo.2016.3709. View

Azuaje F . Computational models for predicting drug responses in cancer research. Brief Bioinform. 2016; 18(5):820-829. PMC: 5862310. DOI: 10.1093/bib/bbw065. View

Chen H, Shen J, Choy E, Hornicek F, Duan Z . Targeting protein kinases to reverse multidrug resistance in sarcoma. Cancer Treat Rev. 2016; 43:8-18. PMC: 4735639. DOI: 10.1016/j.ctrv.2015.11.011. View

10.

Ellner S, Geber M, Hairston Jr N . Does rapid evolution matter? Measuring the rate of contemporary evolution and its impacts on ecological dynamics. Ecol Lett. 2011; 14(6):603-14. DOI: 10.1111/j.1461-0248.2011.01616.x. View

11.

Tian X, Zhang H, Xing J . Coupled reversible and irreversible bistable switches underlying TGFβ-induced epithelial to mesenchymal transition. Biophys J. 2013; 105(4):1079-89. PMC: 3752104. DOI: 10.1016/j.bpj.2013.07.011. View

12.

Gatenby R, Silva A, Gillies R, Frieden B . Adaptive therapy. Cancer Res. 2009; 69(11):4894-903. PMC: 3728826. DOI: 10.1158/0008-5472.CAN-08-3658. View

13.

Qomlaqi M, Bahrami F, Ajami M, Hajati J . An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol. Math Biosci. 2017; 292:1-9. DOI: 10.1016/j.mbs.2017.07.006. View

14.

Goetz M, Gradishar W, Anderson B, Abraham J, Aft R, Allison K . NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019; 17(2):118-126. DOI: 10.6004/jnccn.2019.0009. View

15.

Flavell R, Sanjabi S, Wrzesinski S, Licona-Limon P . The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 2010; 10(8):554-67. PMC: 3885992. DOI: 10.1038/nri2808. View

16.

Rajabi M, Mousa S . The Role of Angiogenesis in Cancer Treatment. Biomedicines. 2017; 5(2). PMC: 5489820. DOI: 10.3390/biomedicines5020034. View

17.

Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz J, Denkert C . The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2014; 6(1):570-83. PMC: 4381616. DOI: 10.18632/oncotarget.2677. View

18.

Hughes J, Hellmann J, Ricketts T, Bohannan B . Counting the uncountable: statistical approaches to estimating microbial diversity. Appl Environ Microbiol. 2001; 67(10):4399-406. PMC: 93182. DOI: 10.1128/AEM.67.10.4399-4406.2001. View

19.

Langley R, Fidler I . The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011; 128(11):2527-35. PMC: 3075088. DOI: 10.1002/ijc.26031. View

20.

Welch D, Hurst D . Defining the Hallmarks of Metastasis. Cancer Res. 2019; 79(12):3011-3027. PMC: 6571042. DOI: 10.1158/0008-5472.CAN-19-0458. View